Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer

Sponsor
The First Affiliated Hospital of Xiamen University
Study ID
NCT06188455
Phase
PHASE3
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Fluzoparib Capsules — DRUG
    Oral administration of 100 mg, 2 capsules/time (50 mg/capsule), twice daily
  • Apatinib Mesylate Tablets — DRUG
    Oral administration of 250 mg each time, 1 tablet/time (250 mg/tablet)

Study Details

Thirty-seven women aged 18-75 years with recurrent ovarian cancer were enrolled

Key Dates

Start date
Dec 1, 2024
Status verified
Oct 2023
Primary completion
Dec 1, 2025
Completion
Dec 1, 2026

Study Design

Enrollment
37 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Fuzuloparib With Apatinib Mesylate Tablets

Primary Outcome Measure

PFS [ Time Frame: up to12 months ]

Related Studies